Panchrotal wrote:諾貝爾獎的得主也只能做千人規模實驗。
誰說沒有組織願意大規模仔細研究它的功效？
有喔
Iv發明人日本諾貝爾獎教授大村智親自主持
千人規模Ivermectin對新冠肺炎療效臨床試驗
試驗已經做一段時間了
預計2021年底會完成
千人規模很大嗎？一般藥的三期都是好幾萬人...
有想過為什麼只有千人規模？應該是沒錢吧。
根本沒有藥廠或政府要贊助相關研究...
提一下最近(今年5/6月與7/8月)兩篇回顧型(review)的論文，
其中一篇說總共有3406個參與者。
規模不夠大，結果就是沒人相信。
看看回顧的臨床資料，
都不是來自歐美國家(我們眼中的落後國家)。
歐美國家確診病例這麼多，
竟然沒有臨床資料可以參考，真的很怪，是不是？
這兩篇的結論基本上都是正面的，
結論貼在下面，細節請自己看。
我覺得值得再投資源進去研究清楚。
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
Conclusions:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
Panchrotal wrote:哪篇論文說無效？沒證據敢亂說？
說無效的論文就是既得利益者為了金錢打壓
都只敢說沒證據證明真的有效，或者實驗條件控制不佳、個案少可信度低而已。
臨床實驗上，用Ivermectin治療的病人情況沒變差，
誰敢說它沒效？
